Therapeutic RANKL inhibition via monoclonal antibodies achieved CNS-specific immunomodulation, effectively suppressing encephalomyelitic progression while preserving peripheral adaptive immunity, suggesting that RANKL could be a potential therapeutic target for treating autoimmune diseases in the CNS. This evidence concerns the gene TNFSF11 and autoimmune disease.